三期临床-话题@MedSci

#三期临床#

55篇内容 | 1924人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1991305, encodeId=99091991305d1, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=针对Tau蛋白的老年性痴呆“特效药”LMTX三期临床试验失败，未来前景难测, objectType=article, longId=74010, objectId=4ecce4010b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ecce4010b6, replyNumber=0, likeNumber=54, createdTime=2017-04-27, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ecce4010b6, moduleTitle=针对Tau蛋白的老年性痴呆“特效药”LMTX三期临床试验失败，未来前景难测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ecce4010b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991304, encodeId=5e651991304d1, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=晚期前列腺癌药物Galeterone三期临床失败, objectType=article, longId=73926, objectId=fd8ae3926ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd8ae3926ec, replyNumber=0, likeNumber=70, createdTime=2017-02-21, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd8ae3926ec, moduleTitle=晚期前列腺癌药物Galeterone三期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd8ae3926ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991303, encodeId=f35f199130305, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=PD-1/IDO组合注册试验开始，小分子IO药物进入三期临床, objectType=article, longId=71603, objectId=a6f3e160391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6f3e160391, replyNumber=0, likeNumber=76, createdTime=2017-04-14, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6f3e160391, moduleTitle=PD-1/IDO组合注册试验开始，小分子IO药物进入三期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6f3e160391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991300, encodeId=437a1991300f6, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=GW制药领军药Epidiolex三期临床成功，股价立马翻倍！, objectType=article, longId=65156, objectId=901d6515625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=901d6515625, replyNumber=0, likeNumber=65, createdTime=2016-05-05, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=901d6515625, moduleTitle=GW制药领军药Epidiolex三期临床成功，股价立马翻倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=901d6515625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991301, encodeId=78c81991301e7, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=JCO：卵巢癌新药Farletuzumab三期临床试验结果发表，3年前已完成试验，结果阴性, objectType=article, longId=65679, objectId=6781656e9f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781656e9f0, replyNumber=0, likeNumber=67, createdTime=2016-08-29, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781656e9f0, moduleTitle=JCO：卵巢癌新药Farletuzumab三期临床试验结果发表，3年前已完成试验，结果阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781656e9f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991307, encodeId=40ed199130e45, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=【盘点】新药LMTX三期临床试验失败，再看阿尔兹海默症前沿进展, objectType=article, longId=74291, objectId=1a3ce429101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a3ce429101, replyNumber=0, likeNumber=80, createdTime=2016-09-24, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a3ce429101, moduleTitle=【盘点】新药LMTX三期临床试验失败，再看阿尔兹海默症前沿进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a3ce429101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991302, encodeId=02ce1991302de, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Blood：B型血友病治疗药物rIX-FP三期临床试验成功, objectType=article, longId=66351, objectId=b1f3663513b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1f3663513b, replyNumber=0, likeNumber=89, createdTime=2016-05-31, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1f3663513b, moduleTitle=Blood：B型血友病治疗药物rIX-FP三期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1f3663513b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991299, encodeId=ed39199129973, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验, objectType=article, longId=58535, objectId=9edb5853543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9edb5853543, replyNumber=0, likeNumber=60, createdTime=2016-05-21, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9edb5853543, moduleTitle=上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9edb5853543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991296, encodeId=4d6e1991296e0, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, objectType=article, longId=45436, objectId=04d8454369d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04d8454369d, replyNumber=0, likeNumber=79, createdTime=2015-06-14, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04d8454369d, moduleTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04d8454369d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991298, encodeId=bb3d199129857, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=国自主知识产权抗癌中药注射液在美获准三期临床, objectType=article, longId=52631, objectId=8b55526317a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b55526317a, replyNumber=0, likeNumber=65, createdTime=2015-07-15, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b55526317a, moduleTitle=国自主知识产权抗癌中药注射液在美获准三期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b55526317a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991295, encodeId=e73b199129595, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Nat Rev Drug Discov：血管生成素抑制剂 trebananib三期临床失败, objectType=article, longId=43656, objectId=672943656a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=672943656a5, replyNumber=0, likeNumber=51, createdTime=2015-06-12, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=672943656a5, moduleTitle=Nat Rev Drug Discov：血管生成素抑制剂 trebananib三期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=672943656a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991297, encodeId=c8ef199129e73, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=武田多发性骨髓瘤药物ixazomib三期临床显示预期疗效, objectType=article, longId=47035, objectId=ed9e4e0358a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed9e4e0358a, replyNumber=0, likeNumber=48, createdTime=2015-06-20, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed9e4e0358a, moduleTitle=武田多发性骨髓瘤药物ixazomib三期临床显示预期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed9e4e0358a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991293, encodeId=594a1991293a0, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=nivolumab黑色素瘤三期临床疗效明显提前终止, objectType=article, longId=37144, objectId=b9103e14463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9103e14463, replyNumber=0, likeNumber=58, createdTime=2014-08-06, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9103e14463, moduleTitle=nivolumab黑色素瘤三期临床疗效明显提前终止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9103e14463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991294, encodeId=22f319912947a, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Endo、BDSI止痛药物三期临床研究获得良好结果即将申报FDA, objectType=article, longId=37657, objectId=3b3f3e657f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b3f3e657f3, replyNumber=0, likeNumber=67, createdTime=2015-06-17, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b3f3e657f3, moduleTitle=Endo、BDSI止痛药物三期临床研究获得良好结果即将申报FDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b3f3e657f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991292, encodeId=56de19912923a, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=我国治疗性乙肝疫苗乙克三期临床试验获阶段性结果, objectType=article, longId=3307, objectId=af02330e28, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af02330e28, replyNumber=0, likeNumber=81, createdTime=2011-11-20, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af02330e28, moduleTitle=我国治疗性乙肝疫苗乙克三期临床试验获阶段性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af02330e28)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

三期临床

2020-05-29

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

针对Tau蛋白的老年性痴呆“特效药”LMTX三期临床试验失败，未来前景难测

2017-04-27

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

晚期前列腺癌药物Galeterone三期临床失败

2017-02-21

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

PD-1/IDO组合注册试验开始，小分子IO药物进入三期临床

2017-04-14

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

GW制药领军药Epidiolex三期临床成功，股价立马翻倍！

2016-05-05

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

JCO：卵巢癌新药Farletuzumab三期临床试验结果发表，3年前已完成试验，结果阴性

2016-08-29

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

【盘点】新药LMTX三期临床试验失败，再看阿尔兹海默症前沿进展

2016-09-24

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Blood：B型血友病治疗药物rIX-FP三期临床试验成功

2016-05-31

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验

2016-05-21

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时

2015-06-14

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

国自主知识产权抗癌中药注射液在美获准三期临床

2015-07-15

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Nat Rev Drug Discov：血管生成素抑制剂 trebananib三期临床失败

2015-06-12

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

武田多发性骨髓瘤药物ixazomib三期临床显示预期疗效

2015-06-20

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

nivolumab黑色素瘤三期临床疗效明显提前终止

2014-08-06

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Endo、BDSI止痛药物三期临床研究获得良好结果即将申报FDA

2015-06-17

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

我国治疗性乙肝疫苗乙克三期临床试验获阶段性结果

2011-11-20

科室
- - 订阅+
  - 更多科室
工具
服务